Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4070)	12/22/2015 10:29:00 AM
From: mulanoon2007	1 Recommendation Recommended By civic08801 Respond to of 4474

I certainly give credence to your opinion that PON might have advantages over ABL-001+NIL in IMA-R/R pts. Although I think the Haematologica report is more important than what meets the eye (i.e. it might not be a case of getting lucky with a handful of patients), the weight of NVS will keep the pressure on PON through aggressive trial execution and thought leader support. FWIW i think the 2L trial of PON is sensible because not only are =/>2% of pts each year falling into the IMA R/R category (i.e. =/>2k/year in the USA) but because of the drive to reach MR4.5 for drug cessation; tea leaves suggest that PON is likely to be more effective than NIL, DAS and BOS.